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Alginate for cardiac regeneration: From
seaweed to clinical trials
Albert Liberski*, Najma Latif, Christophe Raynaud, Christian Bollensdorff, Magdi Yacoub
ABSTRACT
Heart failure is a growing endemic in the aging Western population with a prevalence of over
20 million people worldwide1. Existing heart failure therapies are unable to reverse heart failure
and do not address its fundamental cause, the loss of cardiomyocytes2. In order to induce
myocardial regeneration for the myocardium and the heart valve, facilitate self-repair, improve
tissue salvage, reduce or reverse the adverse-remodeling and ultimately achieve long-term
functional stabilization and improvement in the heart function, novel strategies for therapeutic
regeneration are being developed which are aiming to compensate for the insufficient and low
intrinsic regenerative ability of the adult heart3. Similarly, valve replacement with mechanical or
biological substitutes meets numerous hurdles. New approaches using multicellular approaches
and new material are extensively studied. Most of those strategies depend on biomaterials
that help to achieve functional integrated vasculogenesis and myogenesis in the heart/tissue.
Especially for failed heart valve function a number of therapeutic approaches are common from
corrective intervention to complete replacement4. However the complexity of the heart valve
tissue and its high physical exposure has led to a variety of approaches, however therapeutic
regeneration needs to be established. Beside other approaches alginate has been identified as
one building block to achieve therapeutic regeneration.
Alginate is a versatile and adaptable biomaterial that has found numerous biomedical
applications which include wound healing, drug delivery and tissue engineering. Due to its
biologically favorable properties including the ease of gelation and its biocompatibility, alginate-
based hydrogels have been considered a particularly attractive material for the application in
cardiac regeneration and valve replacement techniques. Here, we review current applications
of alginate in cardiac regeneration as well as perspectives for the alginate-dependent, cardiac
regeneration strategies.
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BACKGROUND: GENERAL PROPERTIES OF ALGINATE
Alginate is a naturally occurring polysaccharide typically extracted from brown seaweeds
and has beenwidely utilized as a hydrogel for tissue engineering5. Alginate can be obtained
with a wide range of molecular weights (typically 32–400 kDa)5–7 and is characterized by
long chains that contain two different acidic components; namely, α-L-guluronic acid (G)
and 1,4-linked β-D-mannuronic acid (M) (see Figure 1).
The overall ratio of both acids, M/G, and the way in which the G andM units are arranged
in the chain, can vary from one species of seaweed to another. The origin and conditions
of the extraction procedure can affect the viscosity of aqueous alginate solutions, lowering
it if conditions are too arduous.
The strength of the alginate hydrogels can also vary from one alginate to another.
For example, with a careful extraction procedure, Laminaria hyperborea gives strong
hydrogels, while Laminaria digitata gives a soft-to-medium strength hydrogels8. Bacterial
biosynthesis may provide an alginate with more defined chemical structures than that
obtained from seaweed-derived alginate9. Generally, alginates with low M/G ratio will give
a stronger hydrogels.
Alginates possess several crucial properties whichmake them suitable for use in cardiac
regeneration. The first is their ability to be dissolved in water to yield aqueous solutions
with moderate viscosity, which is particularly important for formulating injectable mixtures
for cardiac therapies. The second is their ability to form hydrogels in mild conditions, for
example by adding calcium salt to an aqueous solution of alginate. The calcium cations
displace the sodium from the alginate, and grasp the long alginate molecules together,
resulting in a hydrogels (see Figure 1). This property could be used to immobilize the cells
in the desired area of the heart.
In contrast to the agar gels, where the solutions must be heated to about
60–80◦C (depending on type) to dissolve the agar and the gel forms when cooled below
approximately 40◦C, no heat is required to form the alginate hydrogel; moreover, the
hydrogels do not melt when heated. The ionically-triggered gelation of alginate is chemo-
reversible, while covalent cross-linking is permanent (most often by standard carbodiimide
chemistry or photo crosslinking10), and therefore, it is possible to modulate degradation
rates and mechanical stiffness by choice of the appropriate crosslinking agents11,12.
Different chemical and photo based ways can be used to do some crosslinking10,13–17.
The next pivotal property of alginates is their ability to form films18,19, fibers20–22,
beads23 and virtually any shape in a variety of sizes (see Figure 1C). Moreover, as the partial
oxidation of alginate does not significantly interfere with its hydrogels forming capability,
the customized degradation of alginate could be induced by periodate oxidation of the
alginate backbone24.
Within the field of biomedicine, the scope of alginate application is broad and includes
wound healing, cell transplantation, delivery of bioactive agents such as chemical
drugs and proteins, heat burns, acid reflux and weight control applications5,25. The
non-thrombogenic nature of this polymer has made it an attractive candidate for cardiac
applications26–28, including scaffold fabrication for heart valve tissue engineering29.
There are two main solid forms of alginate used in cardiac regeneration; namely,
hydrogels and porous 3D scaffolds. The hydrogel can contain over 99% water trapped
in the network of water-insoluble polymer chains. Two groups demonstrated that using
a three step protocol where alginate is first cross-linked before being frozen and finally
dried and this freezing method could dictate the organization of the pores created in the
scaffold. If the freezing of the cross-linked alginate is done in a homogenous atmosphere
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Figure 1. Alginate structure. The schematic model of hydrogel formation (A). Reprinted with
permission from [2]. Versatility of alginate shaping. Alginate shaped in tricuspid valve, ventricular
view (B1), atrial view, side view (B2), hinge - atrial view (B3), and open valve view (B4). (Scale bars 1 cm.)
of –20C the resulting scaffolds have an isotropic structure with spherical pore, while if
freezing is performed by dipping one end of the scaffold in liquid nitrogen, this create
a gradient of temperature leading to an anisotropic structure (see Figure 2)30–32. This
technique was later commercially used by Life Technology inc. to propose a commercial
3D cell culture system with possibility of orientation under the name of AlgiMatrixTM.
Depending on the freezing regime, the hydrogels could become 3D scaffold with
interconnected pores (up to 200 µm in diameter, and 90% of matrix porosity)32. Ruvinov
et al. reported that freezing of calcium cross-linked alginate solutions in homogenous
cold atmosphere yields isotropic pore structure with interconnected spherical pores,
while applying temperature gradient results in an anisotropic pore structure (see
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Figure 2. Alginate scaffold architecture affects tissue morphology and cell behavior. Depending
on the freezing regime, the scaffolds can be prepared with isotropic (A) or anisotropic (B) pore structure.
The pore dependent cell organization in the scaffold: cells cultivated in anisotropic (C, magnified in D),
and spheroids grown in isotropic alginate scaffolds (E). Reprinted with permission from [32].
Figure 2)32. Importantly, the alginate structure architecture was shown to influence
the cells’ organization (spheroidal, anisotropic) within the pores.
ALGINATE CONTAMINANTS AND RELATED HAZARDS
There are several potentially harmful contaminants that may be carried by alginates
and even accumulated during the alginate production processes. The most important
from the point of treating heart failure are: heavy metals, formaldehyde, polyphenolic
compounds and bacteria. In the case of alginates derived from seaweeds, the heavy metal
content depends on the area and time of plant harvesting. Despite the strict regulation
many ships are painted using paints containing heavy metals that prevent the growth of
marine organisms33. The paints can release the metals which may accumulate especially
in seaweeds that grow close to the sea communication routes. Moreover, despite strict
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regulation, some ships’ owners choose to cut the exploitation costs by disposing of the
waste oils directly to sea water. This may also locally increase the amount of heavy metals
in seaweeds exposed to such wastes. Heavy metals have a high affinity for sulfhydryl
(-SH) groups, inactivating numerous enzymatic reactions, sulphur-containing antioxidants
and amino acids with subsequent increased oxidative stress. This may result in vascular
disease, hypertension, coronary heart disease and myocardial infarction34.
As with all polymers, alginates can also be degraded by reactive oxidate species.
The formation of these species may be catalyzed by Cu+2, Fe+2 and Fe+3 ions. Those
ions have a high affinity for alginates and can accumulate in their production. Therefore,
these species should be removed from alginate, especially for its use in biomedical
applications35.
Similarly aldehydes could be transferred from seaweed to the heart with an alginate
injection, nevertheless animal studies showed that the direct action of formaldehyde on
the heart plays only a minor role36. The negative chronotropic effect of formaldehyde in
animals is caused mainly by the inhibition of sympathetic nervous activity through the
central nervous system.
Polyphenolic compounds could be found in alginates. Surprisingly most of literature
sourcesmention its positive effect on the heart mediated by reduction of oxidative stress37.
Nevertheless, Paracelsus’ law states the action of a chemical depends on the dose of
active agent. It is known that certain polyphenols may have genotoxic and carcinogenic
effects. Furthermore, polyphenols may indirectly inhibit iron absorption which may lead
to local iron depletion. Moreover, polyphenols may interact with certain pharmaceutical
agents and enhance their biologic effects38. Nothing is known about administrating
polyphenols directly to the heart, therefore removing polyphenolic compounds from
biomedical alginates should eliminate possible risks.
Other potential contaminants of alginates include mould, yeast and bacteria, the latter
may contribute to the presence of endotoxins, mitogens and pyrogens35. Considering that
proinflammatory cytokines are now thought to play a key role in the pathophysiology
of chronic heart failure39, this contaminant must be reduced, if not eliminated, from
biomedical alginates.
Importantly, ultrapure alginates with strict control of alginate specification can be
obtained via bacterial biosynthesis40. This enables controlling polymer molecular weight,
its distribution, proportion and arrangement of G and M segments.
The production of biomedical alginates is strictly regulated by legislation enforced by a
number of agencies. For example in USA the FDA is responsible for monitoring production
of biomedical alginates35. Due to sharply defined requirements for composition and purity
of biomedical alginate, the price of it is a hundred fold higher than alginates used in food
industry. Therefore, to conduct early stage/ proof of concept experiments, the cheaper
product may be used but only with awareness of restrictions that will require upgrading
when approaching clinical applications.
ALGINATE HYDROGEL BIODEGRADATION AND CLEARANCE
The degradation, uptake andmetabolismof alginate occurs in several types of bacteria. The
class of enzymes called alginate lyases (Alys) catalyzes an endolytic β-elimination reaction
that leads to depolymerization of alginate into oligomers41. Exolytic enzymes known as
oligoalginate lyases are responsible for further degradation of oligomers into unsaturated
monomers. Some specialized microorganisms degrade alginates and produce ethanol.
This process could be efficient enough to consider alginate as feedstocks for bioconversion
into biofuels and commodity chemical42.
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Importantly, the sameor similar degradation pathwayswere not discovered inmammals,
thus alginate polymers are considered not to be biodegradable in the human organism32.
One benefit resulting from that discrepancy between bacteria and mammals is that
enzymes such as Alys can be safely used to remove alginate from maturing cell-laden
scaffolds. This was reported by Takeuchi, who enzymatically removed the alginate envelope
without harming encapsulated cells in the process of production of the ‘‘living threads’’21.
In the literature there are frequently repeated opinions describing chains of alginate
to be stable under physiological conditions32,43,44. Unfortunately such observations are
insufficient to provide any insight into the fate of alginate injected in the heart. In this work,
we present available reports retrospectively and our direct contribution into understanding
what could happen with alginate injected into the human heart is therefore limited to
identifying the niches and needs for further research. Below we are presenting several
reports that can be used as a starting point for further experimental efforts.
Perhaps the most comprehensive, but still not gap- free discussion on alginate
degradation, was proposed by Andersen and colleagues35. In their dissertation, they
referred to the most commonly applied way of cross-linking the alginate with calcium
ions. The first step to degradation in that case would be disintegration of material due to
exchange of calcium ions by sodium ions in the physiological environment. The process
of hydrogel disintegration and subsequently releasing alginate in its liquid form is the
only way alginate from the hydrogel can leave the heart. The kinetics of this process is
very difficult to anticipate and more experimental work is needed. It was clearly proven
that even under physiological blood concentration of Ca2+ and Na+ ions, the alginate in a
form of hydrogel can still subsist45,46, so it is reasonable to believe that alginate injected
into the heart will be long lasting even after the concentration of Ca2+ in the hydrogel
drops to the physiological level. The plasma sodium concentration47 is simply insufficient
to completely hinder the cross linking effect of Ca2+45,46. Whenever the alginate polymer
molecule finds its way into the blood, the following cascade of events occurs.
After hydrogel degradation the subsequent degradation of alginate will depend on the
rate of cleavage of the glycosidic linkages in polymer chains. Anderson et al.37, estimated
that alginate with Mw 200000 Da will degrade to 100000 Da at pH 7.4 and 37◦C in 80
days. This renders the alginate as stable in physiological conditions.
The exact mechanism of alginate processing in the human body has not been yet
elicited. The only light on that matter was illuminated by Duncan et al.48. To monitor the
fate of alginate following intravenous, intraperitoneal and subcutaneous administration
into mice, they developed a method based on the covalent incorporation of tyrosinamide
into the alginate chains. The product could be radioiodinated to a high specific activity.
Twenty-four hours after intravenous administration the larger polymer fraction remained
in the circulation and did not readily accumulate in any of the tissues, while the low
molecular weight fraction (≤48,000) of the injected polymer was excreted in the urine.
At the same time point after intraperitoneal injection almost all dose of labeled alginate
transferred from the peritoneal cavity to the blood compartment. Following subcutaneous
administration, more than 70% of the injected dose was retained at the site of injection
at 24h.
Even if the hydrogel decomposes, the average molecular weights of many commercially
available alginates are higher than the renal clearance threshold of the kidneys. Therefore,
the alginates should be carefully composed of a molecular weight, to enable controlled
degradation and complete or close to complete removal from the body. To serve the
proposed governing degradation rates, there are a few well-described tools. For example,
at pH 7.4, alkaline β elimination is dominating the degradation path. This may be increased
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Figure 3. Schematic overview of restoration of the dilated ventricle. In accordance to Laplace’s
law, left ventricular wall stress (S) is reduced by increasing the thickness of the wall (T), and reducing
chamber diameter (D). This occurs due to the alginate injections; consequently progressive remodeling
may be reversed or stabilized. Reprinted with permission from [56].
5-fold by introducing to alginate chains the Periodate oxidate residues35,49. The side effect is
to increase chain flexibility which leads to formingweaker gels. The degradation of alginates
can also be enhanced by Gamma irradiation50. In that case, the degradation seems to
follow the pattern of random depolymerization with no preference for specific residues35.
Many signaling pathways of cardiac cells, especially regulating heart performance51,
depends on the concentration of calcium. The calcium injected into the heart with alginate
hydrogel may cause long lasting environmental changes to surrounding tissue45, which
may result in impaired myocardial function and cardiac relaxation and ultimately in heart
failure52. Therefore, to avoid the risk, the amount of the calcium in the hydrogel should be
close to physiological levels. In one report authors used 1% (wt/vol) alginate and 0.3%
(wt/vol) calcium gluconate53 so the concentration of Ca+2 is about 28 mg in 100 mL of
hydrogel, while normal blood calcium concentration is up to 10.5 mg per 100 mL. This
makes the question of kinetics of release of calcium from alginate hydrogel evenmore vital.
CURRENT APPLICATION OF ALGINATE AS A BIOMATERIAL IN CARDIAC
REGENERATION
Currently the most advanced clinical trials, involving alginate based systems, for cardiac
regeneration, includes Algisyl-LVRTM sponsored by LoneStar Heart, Inc (Laguna Hills, CA,
USA) and PRESERVATION 1 sponsored by Bellerophon BCM LLC (Hampton, NJ, USA). These
trials were preceded by extensive animal studies (pigs, dogs and rats), the key part of
which is summarized below.
Ventricle restoration by injecting cell-free alginate implants into the LV wall
The group of Randal J Lee evaluated the efficacy of alginate hydrogel implants in dogs with
heart failure (HF) induced by repetitive coronary microembolization54. During an open-
chest procedure, dogs received the injection mixture prepared by combining sodium-
alginate aqueous solution with calcium cross-linked alginate hydrogel. Two weeks after
the last microembolization, material was applied by 7 injections into the LV wall, halfway
between the base and the apex, see Figure 3. After 24 h, the electrocardiography showed
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Figure 4. Transmural section from the LV in a control dog and a dog treated with alginate
hydrogel implant (AHI). Reprinted with permission from [54].
Table 1. In-man experience with LV restoration in patients with systolic heart failure (reprinted with
permission from [54] ).
Presurgery Post 3 days Post 8 days Post 3 months
LVEF (%) 28.7± 8.5 37.6± 11.2 36.5± 16.0 36.0± 13.5
LVEDV (ml) 139.5± 20.6 122.5± 13.9 123.5± 45.0 123.6± 18.6
LVESV (ml) 99.8± 25.8 79.5± 22.8 87.2± 46.0 77.2± 29.5
KCCQ score 39.4± 28.0 n/a 53.4± 19.9 74.0± 25.0*
No. of patients in NYHA class III/IV 6 n/a 1 1
Notes.
This is a synopsis of the data presented at the 2010 American Heart Association (AHA) meeting by Dr. Bauernschmitt’s group
(∗p< 0.05). LVEF, left ventricular ejection fraction; LVEDV, left ventricular end diastolic volume; LVESV, left ventricular end sys-
tolic volume; KCCQ, Kansas City Cardiomyopathy Questionnaire; NYHA, New York Heart Association.
no significant differences between saline-treated and the alginate implant groups of
animals with respect to severity of ventricular arrhythmias, heart frequency and rate. Four
months post treatment the implant material was encapsulated by a thin layer of connective
tissue still within the LV free wall. No evidence of inflammation was observed, see Figure 4.
Compared to control, the alginate implantation significantly increased ejection fraction,
wall thickness, improved LV sphericity, reduced LV end diastolic pressure as well as
end-diastolic and end-systolic volumes.
These encouraging preclinical results have led to the initiation of clinical investigation for
intramyocardial delivery of alginate implants in patients with acute myocardial infarct (MI).
Alginate implants, under the name of Algisyl R©, were classified as a medical device
(disputable, official FDA qualification), consist of Na+-alginate and Ca2+-alginate55, are
dedicated for patients with enlarged left ventricle (LV) resulting from a mitral valve
regurgitation, MI, arrhythmias and ischemia. The product comprises alginate that is
administered directly into the left ventricle wall using up to 19 injections. Alginate remains
in the heart muscle acting to increase pumping efficiency, reduce left ventricular wall stress,
and prevent further dilation and negative remodeling of the left ventricle (see Figure 3).
Also in human studies56, implementing alginate within the ventricular wall has been
shown to reduce the wall stress of the dilated heart and relieve the muscle tension56.
The studies by Lee et al. indicated significant improvements in the ejection fraction
(18% increase after 3 months post injection) and other cardiomechanical parameters, all
summarized in Table 1 and favourable biological effects such as tissue regeneration and
neovascularization.
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The other advantages of this alginate based treatment are that it does not interfere
with drug therapies and procedures such as valve or bypass surgery57, transplantation
or Left Ventricular Assist Devices (LVADs). Moreover, as a one-time procedure, it is less
time consuming, more efficient and cost-effective in comparison to active implantable
devices that require a power source. Since the group of patients in the Lee studies was
small, namely two patients with non-ischemic and four patients with ischemic dilated
cardiomyopathy, and follow-up of 3 months only on one patient, the results were to be
confirmed in clinical trials on a wider group of 76 patients (ClinicalTrials.gov Identifier:
NCT01311791). Final data collection date for primary outcome measure was assigned on
April 2014, but the estimated study completion date is April 2016. This study is ongoing
and no results currently posted on ClinicalTrials.gov.
Subsequently, the manufacturer of Algisyl-LVR (LoneStar Heart, USA), instigated a
research grant with the objective of comparing alginate-hydrogel injections with standard
medical therapy to determine the impact on clinical outcomes in patients with advanced
heart failure58,59. The authors found that alginate-hydrogel injections in addition to
standard medical therapy for patients with advanced chronic HF was more effective
than standard medical therapy alone for improving symptoms and exercise capacity.
Thirty-five patients were treated with thoracotomy assisted, alginate-hydrogel injections59.
Alginate-hydrogel treatment was associated with improved peak oxygen uptake on
cardiopulmonary exercise59 at 6 months compared to control. Also six-minute-walk-test
distance improved in alginate-hydrogel-treated patients versus patient treated by standard
medical therapy. The study was conducted at 14 centres in Australia, Germany, Italy, the
Romania, and Netherlands, however researchers should have indicated more precisely
what ‘‘standardmedical therapy’’ means, as it may be an important variable. Unfortunately,
the 30-day surgical mortality was 8.6% (3 deaths) which is not superior but neither inferior
in comparison to the outcome of other devices currently under investigation, for example
HeartNet device60 (Paracor Medical Inc.), the Parachute device61 (Cardikinetix), Revivent
device62 (Bioventrix).’’
TREATING MYOCARDIAL INFARCTION BY INJECTING ALGINATE IN CORONARY ARTERY
Similar way of applying alginate to cardiac regeneration was investigated by Landa et
al.53. In this study rats were used as a model. Calcium-crosslinked alginate solution
was prepared from an aqueous solution by mixing it with calcium gluconate solution.
Importantly, for temporal tracking of the injectable alginate biomaterial in infarcted hearts,
biotin-labeled alginate was used. This was injected into the infracted area 7 days after
anterior myocardial infarction. In situ formed hydrogel occupied 50% of the scar area.
Alginate was replaced by connective tissue within 2 months, echocardiography studies
showed that injection of alginate biomaterial reduced left ventricular diastolic and systolic
dilatation, and dysfunction. The results were compared to those achieved by neonatal
cardiomyocyte transplantation and were found to be superior (see Figure 5).
Authors concluded that injection of bioabsorbable, in situ–forming, alginate hydrogel
is a feasible acellular strategy that prevents adverse cardiac remodeling and dysfunction
in recent and old myocardial infarctions. Authors avoided addressing the potential risk
of calcification of heart tissue related to the increased concentration of calcium ions.
Depending on the method a 5% CaCl2 (∼ 450mM) solution can be used to harvest
solidified alginate63. Perhaps this is due to recent reports describing anti-mineralization
effect of alginate on porcine and human cardiac valves64.
Similar animal studies were carried out on larger animals by Leor and colleagues65. They
prepared calcium cross-linked alginate solution that undergoes liquid to hydrogel phase
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Figure 5. Infarcted rat hearts after immunostaining for α-SMA, after treatment with
alginate or cardiomyocyte transplantation. In the scar tissue 8 weeks after alginate injection,
extensive positive brown staining revealed that the scar was populated with α-SMA positive
myofibroblasts (A,B). Fewer myofibroblasts were observed for control scar to which the cell culture
medium was injected in place of alginate (C). Neonatal cardiac cell implant (arrow) at the border of the
infarct zone 8 weeks after transplantation (D). Engrafted cells were undifferentiated and isolated from the
host myocardium. Reprinted with permission from [53].
transition as previously studied after injection into the infarct-related coronary artery in
swine. Examination of hearts harvested 2 hours after injection showed that the alginate
crossed the infarcted leaky vessels and was deposited as hydrogel in the infarcted tissue
(see Figure 6A and B).
The authors clearly establish the increased number of myofibroblasts over fibroblasts
in alginate treated tissues compared to saline treated ones. This increased number of
myofibroblasts is believed to be of better outcomes for multiples reasons. First, it is
now established that fibroblasts are involved in formation of the extracellular matrix
and the extent of the extracellular matrix. Excess collagen deposition with a loss of
collagen degradation by matrix metalloproteinases leads to fibrosis which has a long term
impact on the function of the heart. Separation of myocytes by collagenous septa insulates
myocytes and decreases myocyte-myocyte interactions leading to an overall loss of normal
function. Those fibroblast can differentiate into myofibroblasts which are cells involved
in the inflammatory response to injury, as they produce cytokines thus enhancing the
inflammatory response. The complex intracellular structure of myofibroblasts define them
with a contractile mechanism that enables these cells to generate force to the surrounding
extracellular matrix. This contractile force is maintained over time and reinforced by the
deposition of collagen.
Moreover, histological analysis performed 60 days after injection, showed that applying
2 mL of alginate solution increased scar thickness by 53% compared with control and
was replaced by collagen and myofibroblasts (see Figure 6C-F). It highlights indirect
improvement due to additional cells growing. At the same time point the control swine
injected with saline solution experienced an increase in left ventricular (LV) diastolic area
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Figure 6. Infarcted heart after intracoronary injection of calcium cross-linked alginate solution.
120 min after injection, the alginate hydrogel was identified on the infarct surface (A) (arrows). Heart
sections revealed hemorrhagic infarct and in situ deposition of the alginate hydrogel (white areas,
arrows) and consistent distribution of the biomaterial in the granulation tissue (B). Increased thickness
of the scar (black arrows) was induced by alginate implant 60 days after (C & D). Infarcted hearts after
immunostaining for α-SMA, 3 months after alginate (E) or saline injection (F). Smooth muscle actin
positive myofibroblasts were predominantly observed when alginate was injected to scar area. Reprinted
with permission from [65].
by 44% and LV systolic area by 45%. The authors concluded that intracoronary injection of
alginate biomaterial is safe, feasible, effective, could be used as an intervention to prevent
adverse remodeling and improve infarct repair after myocardial infraction. Unfortunately,
the authors did not discuss risks related to increased calcium concentration induced by
calcium-cross-linked alginate, which includes calcification of the heart tissues64,66,67.
Unlike in the previous approach where alginate is injected in the wall of the ventricle
and remains in place encapsulated by a thin layer of connective tissue, when injected in
the coronary artery, the alginate is rapidly replaced by collagen and myofibroblasts.
A very elegant, but still proof-demanding explanation, on how alginate acts in the
infarct area was proposed by Ruvinov and colleagues in their outstanding review32. They
concluded that the elevated calcium concentration at the acute infarct site causes local
crosslinking of alginate, its rapid gelation and phase transition into a hydrogel. While
Page 12 of 25
Liberski et al. GCSP 2016:4
the tissue is healing, the calcium concentration drops and alginate crosslinking reverse.
Indeed, the average calcium concentration in the blood stream is 9.5 mg/dl, which is too
low to maintain the grasp of the long alginate molecules together. After administration,
the alginate hydrogel degrades and disappears from the infarct zone and is replaced by
host tissue composed of myofibroblasts enriched with blood capillaries53,65.
These promising results have led to the launching of clinical investigations of
intracoronary delivery of alginate biomaterial in patients with acute MI by Bellerophon
(ClinicalTrials.gov Identifier: NCT01226563). They used the aqueous mixture of sodium
alginate and calcium gluconate as a bioabsorbable cardiac matrix for preventing
negative ventricular remodeling following acute myocardial infarction68. During standard
catheterization procedure, the hydrogel is injected via the coronary artery into the damaged
heart muscle. Here injected material perfuses and polymerises in sites in between the cells
and fibers of damaged tissue. This provides physical support of the heart muscle during
repair and recovery. It is claimed that alginate gradually dissipates and is excreted through
the kidneys after healing69. While the author concluded on the safety and efficacy of this
approach in human patients, no condition improvement was reported. Ongoing clinical
trials involve approximately 300 patients who had successful percutaneous coronary
intervention following acute ST-segment (ST-specific part of echocardiogram) elevation
myocardial infarction (ClinicalTrials.gov Identifier: NCT01226563).
ALGINATE FOR ANGIOGENESIS: CONTROLLED DELIVERY AND COMPOSITES
The potential use of the different alginate hydrogels as pharmaceutical excipients has
not yet been fully evaluated but alginate is likely to make an important contribution
in the development of polymeric delivery systems. The precise chemical degradation
mechanism and approaches in the choice of alginate for drug deliveries was previously
broadly reviewed70. Briefly, the possibility to form two types of gel with alginate dependent
on pH (acid gel) or ions, gives the polymer more tailored capacities compared to neutral
macromolecules. More than 200 different alginate grades and alginate salts are now
offered. When considered for local injection or oral delivery (oral route being the patient
preferred drug administration), the type of hydrogel used is obviously crucial. Alginates
polymers are one of the most extensively explored mucoadhesive biomaterials thanks to
very good cytocompatibility and biocompatibility, biodegradation and sol-gel transition
properties. But beyond the chemical composition and re-swelling approach chosen,
multiple mechanisms can be considered to control the release speed of a compound
using alginate. First, the size of the hydrogel can be controlled; a higher surface area will
provide more ‘‘space’’ for the molecule to diffuse through the hydrogel. The permeability
of the hydrogel is obviously critical as is the density of the polymer that controls it which
can control the how easily the molecules can diffuse through the polymer network.
Several laboratories have demonstrated the utility of alginate for the controlled delivery
of angiogenic factors. The loss of ion in the alginate hydrogel can trigger their dissolution
therefore crosslinking could be utilized to improve the mechanical stability and control the
degradation kinetics of an alginate hydrogel71–73. For example, Vascular endothelial growth
factor (VEGF) entrapped in the alginate hydrogel has a steady and continuous release
for more than one month74. Free VEGF is degraded within 72 h post-injection while VEGF
injected within the alginate hydrogel is detectable up to 15 days after injection. Moreover,
to enhance affinity to angiogenic factors, alginate can be sulfated such that it mimics
the structure of heparin75 (see Figure 7). This modification of the hydrogel has stronger
binding to Hepatocyte growth factor (HGF) and achieved a higher therapeutic effect than
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Figure 7. Schematic representation of the ‘‘anchoring’’ of the growth factor into alginate sul-
fate (A) and summary of sequential delivery of growth factors from alginate in vivo (B). The faster
release of insulin-like growth factor 1 (IGF-1) could provide strong pro-survival signals at early stages,
while the slower release of HGF could induce angiogenesis at later stages. Reprinted with permission
from [75] and from [32].
the unmodified alginate. All this together makes alginate an interesting candidate as a
biomaterial for enhancing angiogenesis in heart failure.
Hao and colleagues investigated if local sequential delivery of vascular endothelial
growth factor (VEGF) followed by platelet-derived growth factor-BB (PDGF-BB) with
alginate hydrogels could induce a functional improvement and angiogenic effect which
is greater than single factors after myocardial infarction in a rat model76. Hydrogels were
administered intra-myocardially along the border of the myocardial infarction. Hydrogels
comprised low and high molecular weight alginate to enable control of the release
kinetics of incorporated factors74. Hydrogels were capable of delivering the growth factors
sequentially; the VEGF was released faster than PDGF-BB. This led to a higher density of
α-smooth muscle actin positive vessels than in the case of single factors but no increase
was found in capillary density. Sequential protein delivery increased the systolic velocity-
time integral and displayed a superior effect than single factors. In the aortic ring model,
sequential delivery led to a higher angiogenic effect than single factor administration76.
Authors concluded that inducing mature vessels and improving cardiac function could be
enhanced by applying the growth factors sequentially rather than individually indicating
clinical utility.
Finally, alginate has been blended with a conductive polymer namely, polypyrrole to
enhance cardiac cells–implant interaction. The alginate polymer blend was injected into
the infarct zone of the rat heart. At 5 weeks post-treatment, the blend yielded significantly
higher levels of arteriogenesis when compared with the alginate only treatment group and
the saline control group. In addition, the blend enhanced infiltration of myofibroblasts into
the infarct area77. The results of this study highlight the potential of combining alginate
with other biopolymers for application in cardiac regeneration strategies.
In fact, all efforts aiming to enhance and control the conductivity of alginate based
systems are substantial77,78. Electrical, signal may be transduced with different rate,
around the alginate island; this may cause re-entry circuit and in fine arrhythmia79.
Problem of that nature occurred when ischemic heart failure was treated by skeletal
myoblast transplantation80. The one way of solving that problem would be to implant
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cardio-defibrillator (ICD), which can send a high-energy electrical signal to eliminate
arrhythmias. Unfortunately, this device causes a highly unpleasant sensation felt by
the patient81. In a different study it was shown that arrhythmia was avoided when
undifferentiated human ESCs surgically delivered onto the infarct area in a 68-year-old
patient were embedded into a fibrin scaffold82. This is encouraging evidence indicating
the importance of applying hydrogel to enhance performance of cell-base therapies.
ALGINATE BASED PATCHES FOR CELL TRANSFER IN CARDIAC REGENERATION
It is evident that alginate mediated cell delivery can improve cellular viability and
retention65,83,84. Building on this advantage, Dvir and colleagues85 constructed a patch by
seeding neonatal rat cardiac cells isolated from the LV of 2 days old rat heart in Matrigel
(authors failed to describe manufacturer of Matrigel) supplemented with a mixture of
angiogenic and prosurvival factors (insulin-like growth factor-1 (IGF-1), stromal-cell derived
factor 1 (SDF-1), and VEGF into macroporous alginate scaffolds. To promote maturation
of vasculature the patch was cultured for a week in the rat omentum and transplanted
into post-infarction rats. One month after implantation the patch showed electrical and
structural integration with the host myocardium (see Figure 8).
Similar results were reported by Leor and colleagues28 who successfully implanted
cardiac cell-seeded macroporous alginate scaffolds into infarcted rat hearts28. After 24 h,
the fetal rat cardiomyocytes seeded within the scaffolds formed multicellular beating
cell clusters27. Following implantation of the construct with viable cells into the infarcted
myocardium, some of those cells differentiated into mature myocardial fibers. Moreover,
the graft itself and its surrounding tissue vascularized (see Figure 9).
The versatility of alginate enables the preparation of scaffold which is designed
for a specific action and need. For instance Dvir et al. developed 3D nanocomposites
incorporated gold nanowires within macroporous alginate scaffolds to bridge between the
non-conducting pore walls. This enhanced the organization of functioning cardiac tissue
by increasing electrical signal propagation throughout the cell seeded scaffold78 (see
Figure 10). While addressing the risk of reduced propagation of the electric signal within
the scaffold, additional work should be done to analyze the opposite risk that represents
increased velocity of the electric signal propagation.
ALGINATE DERIVATIVES FOR CELL TRANSFER IN CARDIAC REGENERATION
To enhance cellular growth, alginate was modified with Arg-Gly-Asp peptide (RGD) (see
Figure 11A–D). While injected up to 5 weeks post-MI in rat, either modified and unmodified
alginate hydrogels led to increased arteriole presence, improvement in end diastolic and
LV end systolic diameter compared with saline (see Figure 11E & F)86.
Often the peptide-cell interaction could be specific to a given type of cell89; nevertheless,
RGD-peptide -modified-alginate is versatile, thus it was also used to encapsulate human
Mesenchymal Stem Cells (MSCs) for the transfer (see Figure 12. Noteworthy, in vitro, the
cells in the beads after 5 weeks of incubation are still spherical. As it was shown before,
in this shape, they are under the stress but can still grow and proliferate, nevertheless, in
contact with a more cell-‘‘friendly’’ surface, the cells migrate vigorously to it (see Figure
12B blue arrow). This cell affinity difference between the surfaces is vital for cell transfer
applications. Injection of RGD-modified alginate microbeads without and with MSCs in
a 1-week rodent MI, led to improvement in preservation of wall thickness, LV internal
diameter and fractional shortening (FS)88. Nevertheless, the role and benefit of MSCs
injection following MI remain controversial particularly in clinical applications89
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Figure 8. Construction of a cardiac patch in an alginate/alginate-sulfate scaffold capable of
binding and releasing mixed factors. The scaffold features before cell seeding; macroscopic view
(A) and internal porosity by scanning electron microscopy (B). Cardiac patch seeded with cells and
supplemented with factors after 48 h of cultivation. Light microscope view of the cardiac patch showing
uniform distribution of cells in the matrix pores (C). Cardiac cell organization within the scaffold as judged
by anti-actinin immunostaining (green) and nuclear staining (red) (D). Some of the cells reveal the typical
striation of cardiac tissue. Vascularization of the 7 day omentum-transplanted mixture supplemented
cardiac patch. The cardiac patch (arrow) is stitched to the omentum (E). Mature blood vessels populate
the cardiac patch supplemented with factor as judged by anti-SMA immunostaining (brown) (F).
Blood vessel density in the omentum-implanted patches (G). Typical cardiac cell striation is revealed
in an omentum generated, factor-supplemented alginate cardiac patch as revealed by anti-actinin
immunostaining (green) and confocal microscopy (H). Scale bar: 200 µm (C&E); 10 µm (D&H). Reprinted
with permission from [87].
Importantly, the experiment performed by Tsur-Gang et al.90 also on rats and in the
similar time range, showed that unmodified alginate is superior in improvement of scar
thickness and left ventricle dilatation and function, compared with alginates modified with
RGD and YIGSR, as well as with RGE peptide. This discrepancy may be due to reduced
coverage of the infarct resulting from alteration in viscosity of hydrogels upon covalent
attachment of the peptides32. It must also be mentioned that covalently unbounded
peptides entrapped in alginate may hinder the cellular affinity triggered by peptides
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Figure 9. Photograph of heart at day 63 after implantation of cellular construct revealed intense
neovascularization growth into biograft (B). Coronary branch (C) supplies biograft and covers it with
network of vessels. Reprinted with permission from [28].
covalently linked to alginate91. This is because free standing peptide when anchored to
cell receptor blocks the cellular capacity for adherence. For this reason experimenter must
take extra care for the purification of the product prior to using it. This simple validation
of hydrogel purity was not presented in papers discussed here.
POTENTIAL DISADVANTAGES OF ALGINATE AND ITS ALTERNATIVES
Despite its benefits, the alginate based hydrogels have a few important drawbacks. For
example as a natural product its composition may vary from batch to batch which includes
ratio of G- and M- building blocks, molecular weight and molecular weight distribution.
This may have tremendous effect on gelation properties and mechanical properties of
hydrogels which is pivotal for biopolymer performance as a treatment agent. Despite best
efforts, it is still not fully understood. What is the final fate of the injected material? How it
is eroded from the tissue and is excreted from the body? Moreover, in its cross-linked form
alginate is a source of calcium ions. As discussed, that may be associated with a higher
calcification risk. The vital question of whether the presence of calcium alginate in the
human heart enhances, prevents or has no effect on tissue calcification, has not yet been
fully addressed. That is mainly because the process of calcification and its background is
complex and enigmatic, despite outstanding research on the topic92.
Alginate calcification has been reported during animal implantation67,93,94 and
clinically95. Perhaps the most comprehensive studies on alginate mediated calcification
and characterization of themineral was provided by the Schwartz group67. The calcification
process was investigated in nude mice by injecting subcutaneously or intramuscularly
calcium-crosslinked alginate microbeads. In both cases the beads mineralized maximally
6 months after injection. In-depth analysis revealed that calcium phosphate deposited
uniformly on the microbeads. The minerals on the beads’ surface closely matched
hydroxyapatite found in bone. In the same study, the authors evaluated several methods
to regulate or eliminate mineralization. They concluded that replacing calcium by barium,
as well as buffering the crosslinking solution with HEPES, prevents calcification in vivo.
This study confirmed that alginate processing prior to its implantation is necessary to
regulate alginate calcification.
A potential way to circumvent the problem lies in a strategy of mixing the calcium-
crosslinked alginate with an anti-calcification agent57,68. For example, sodium alginate
was shown to slow down calcification64. Kanakis and colleagues crystalized calcium
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Figure 10. Cardiac tissue engineering in nano-composite multifunctional alginate scaffolds.
Schematic overview of three-dimensional engineered nano-wired cardiac tissue: alginate pore walls
(blue), cardiac cells (red) and gold nanowires (yellow) (A). Incorporation of nanowires within alginate
scaffolds (B). Top: typical gold nanowires, bottom: nanowires assembled within the pore walls of the
scaffold. Cardiomyocytes cultured in pristine alginate (a) and in alginate nanowires–composites (c).
Monitoring calcium dye fluorescence for measuring calcium transient propagation within engineered
tissues assessed at points marked with white circles. Calcium transients were only observed at the
stimulation point in the unmodified scaffold (b). Calcium transients were observed at all points of wired
composite (d). Reprinted with permission from [78].
carbonate, using porcine and human cardiac valve leaflets as a substrate, with and
without sodium alginate. For both human and animal tissues, addition of sodium alginate
reduced the rates of crystal growth by over 40%.
It is reasonable to believe that calcification of tissue is regulated by many overlapping
factors that optimally are in balance92,96,97. Indeed, calcium alginate can affect this balance
severely by the adsorption and subsequent blocking of the active growth sites98,99.
Nevertheless, the fact that in the clinical trials discussed above57,68 alginate was not
associated with extensive tissue calcification points to its advantage as a therapeutic
agent, although more research is needed on this subject.
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Figure 11. Culture of HUVECs after 5 days on RGD modified alginate (A) and non-modified
alginate (B). Live (green)/dead (red) assay of (A) (C). Live (green)/dead (red) assay of (B) (D). Trichrome
staining at 5 weeks post-injection of PBS (E) and alginate injected heart (F). Black arrow in (B) indicates
residual alginate in situ. Scale bar: 1 mm. Reprinted with permission from [86].
Due to the potential drawbacks listed above, it is vital to compare this material to
other alternatives that may be superior in any given application. For example, Zafar and
coworkers recently reported bioscaffolds prepared from decellularised, non-crosslinked
extracellular matrix (ECM) derived from small intestinal submucosa. It was used to prepare
a tubular tricuspid valve that showed physiological growth, remodeling and preserved
function100.
Another potentially useful material for a variety of heart repair strategies is bacterial
nanocellulose101. Its superior mechanical properties make it an extremely interesting
candidate to test as a base for cardiac patches or to produce heart valve leaflets, see
Figure 13 for unpublished data.
Also, chitin and chitosan (in combination with other biomaterials) were successfully
used to produce scaffold for heart leaflets102. For the full range of physiological flow
conditions tested, the electrospun gelatin-chitosan polyurethane demonstrated good
biocompatibility and cell retention properties103.
Synthetic polymers may also potentially be used in therapies related to heart failure
and tissue engineering104. For example elastomeric poly(glycerol sebacate) (PGS) was
reported to support in vivo remodeling of cell-free synthetic graft into a neoartery105,106.
Sohier and colleagues proposed applying nano-fibrillar anisotropic poly-(ε-caprolactone)
(PCL), as a substrate for heart valve engineering107.
In their outstanding report Baaijens and coworkers claimed using poly-ε-caprolactone
bisurea strips to modulate macrophage polarization within scaffolds and trigger specific
immune response to enhance deposition of sulphated glycosaminoglycans and collagen
on the scaffolds to support tissue remodeling108.
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Figure 12. RGD-Alginate microbeads after human MSCs encapsulation. 2 days (A) and 5 weeks
after encapsulation (B). Note: cell transfer to tissue culture plastic (blue arrow). 4x and 10x respectively.
Trichrome staining of heart at 10 weeks post-injection of hMSCs encapsulated in RGD-Alginate, red
arrow indicates beads (C). Injection of PBS (control) (D). Vimentin stain (green) for cell retention after 2
weeks post injection of hMSCs microbeads, (E) 10x, and (F) 40x. Blue color: nuclei stain. Reprinted with
permission from [88].
CONCLUSIONS AND FUTURE ALTERNATIVES OF ALGINATE-BASED CARDIAC
REGENERATION TECHNIQUES
Thanks to a variety of crosslinking approaches, alginate can form versatile and tunable
hydrogels, suitable for carrying cells and developing 3-D cellular microenvironments.
Alginate can be modified with a variety of biological agents to promote matrix-cell
interactions, guide 3-D cell organization, modulate cell fate and promote cellular
integration32.
Alginate-based biomaterials for the treatment of MI is entering the clinical trials
stage, therefore understanding the mechanisms by which these therapies affect LV
remodeling, cardiac function and cardiac electrophysiology becomes a pivotal issue.
Despite progress made in cardiac patches and injectable alginates, much of its potential
remains unexplored, including alginate-mediated reprogramming of non-cardiomyocytes
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Figure 13. Bacterial nanocellulose in form of sheet 10×10 cm (A), leaflets immobilized in
transparent PDMS (B-D). Hyaluronic acid-loaded nanocellulose sheets were provided as a gift by Bowil
Biotech, Władysławowo, Poland.
into cardiomyocytes109, alginate as a vehicle for delivering cardiac progenitors cells
and their derivatives, alginate-supported generation of the new cardiomyocytes, and
alginate-assisted activation of endogenous cardiac progenitor cells.
To fully utilize alginate in those applications several challenges still need to be
addressed. Firstly, more cell-interactive alginate derivatives are required to offer a better
precision in controlling cell organization, differentiation, growth and function. Governing
at the micro- and nano-scale, the spatial distribution of signaling and topographical cues
are key tools for designing cell-interactive systems. Next, more tunable alginate-based
release systems need to be developed to improve their safety, obtain local effects and
increase sustainability. The focal point of these efforts is the sequential release of drugs
(small molecules, proteins, nucleic acids) while on-demand drug release could take place
in response to signals derived from cells (ECM degradation or production, apoptosis,
changes in cell populations etc.) and external cues (such as light or mechanical signals,
electromagnetic fields).
Recent achievements in the solid free-form fabrication of alginate-based constructs for
heart valve tissue engineering illustrate the vital direction in which the cardiac regeneration
techniques may develop. Duan et al. used a Fab@Home bioprinter to prepare scaffolds
from gelatin/alginate -blended hydrogels19. Valvular interstitial cells (VICs) and aortic root
sinus smooth muscle cells (SMCs) were encapsulated separately into alginate/gelatin
blend before printing the heart valve root. After one week of culture, the mechanical
properties of the acellular scaffolds were much lower than those of the cell-laden 3D
printed hydrogels. What is now needed is further advancement in 3D deposition methods,
Page 21 of 25
Liberski et al. GCSP 2016:4
Figure 14. Alternative ways of 3D construct fabrication using alginate fibers. Organ weaving:
connecting tissues using gradients (A). An example of manual plain weaving using three cell lines.
Magnified box: basic criss-cross pattern of plain weaving. Overlaid thread containing HepG2 cells and
underlying thread containing HEK-293 cells labeled CellTracker Green CMFDA (B). Fiber-supported
living threads, fluorescence images of double-treated thread, including fluorescently labeled L929 cells
stained with CellTracker Green CMFDA (C) and MCF-7 cells stained with nuclei stain Hoechst-33342 (D).
Overlay of images (C) and (D) showing two distinguishable layers of cells (E). Living thread immediately
after preparation (F). The same after 8 days of incubation (G). Pictures were reprinted with permission
from (10). Fiber-based assembly of higher-order 3D macroscopic cellular structures (H). Fluorescence
micrograph of a HUVEC/ACol (top panel) and primary cortical cell/PCol fiber (bottom panel) at day 35
(I). Scale bars are 20 µm. Schematic of a microfluidic weaving machine working in culture medium (J).
Pictures were reprinted with permission from [11].
focusing on eliciting oriented growth of the cells and the ECM, which may further enhance
cardiac tissues regeneration32,110.
Although 3D printing of alginate based hydrogels is a powerful and feasible technique,
effort is also needed to explore other free-form fabrication technologies. For example
fibers made out of alginate could be processed using weaving, knitting and braiding (see
Figure 14)10,11. Fibers consisting of encapsulated cells (‘‘living’’ threads) are an attractive
option since cells are provided directly into the dedicated location within the structure
avoiding time-consuming cellular diffusion through the construct (see Figure 5A, H)10,11.
It is difficult to deny that replacing vital organs and tissues with fabricated composites
still does not meet all the sophisticated biological and physiological requirements and
reproducing their characteristics remains elusive. Many properties of alginate are not
unique taken separately, but the fact that alginate combines them all makes it a valuable
material that could be used to approach the challenges ahead.
Page 22 of 25
Liberski et al. GCSP 2016:4
ACKNOWLEDGEMENTS
Authors would like to acknowledge Aleksandra M. Liberska and Dr. Brian P. Mitchelson for
their input in improving the manuscript.
REFERENCES
[1] Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart failure. Nat Rev Cardiol. 2011
Jan;8(1):30–41.
[2] Lin Z, Pu WT. Strategies for cardiac regeneration and repair. Sci Transl Med . 2014 Jun 4;6(239):239rv1.
[3] Ruvinov E, Dvir T, Leor JM, Cohen S. Myocardial repair: from salvage to tissue reconstruction. Expert Rev
Cardiovasc Ther . 2008 Jun;6(5):669–86.
[4] Yacoub MH, Takkenberg JM. Will heart valve tissue engineering change the world? Nat Clin Pract
Cardiovasc Med . 2005 Feb;2(2):60–1.
[5] Bidarra SJ, Barrias CC, Granja PL. Injectable alginate hydrogels for cell delivery in tissue engineering.
Acta Biomater . 2014 Apr;10(4):1646–62.
[6] Lee DW, Choi WS, Byun MW, Park HJ, Yu Y-M, Lee CM. Effect of gamma-irradiation on degradation of
alginate. J Agric Food Chem. 2003 Jul 30;51(16):4819–23.
[7] Kong HJ, Smith MK, Mooney DJ. Designing alginate hydrogels to maintain viability of immobilized cells.
Biomaterials. 2003 Oct;24(22):4023–9.
[8] Vauchel P, Kaas R, Arhaliass A, Baron R, Legrand J. A new process for extracting alginates from laminaria
digitata: Reactive extrusion. Food Bioprocess Technol. 2008 Apr 9;1(3):297–300.
[9] Hay ID, Rehman ZU, Ghafoor A, Rehm BHA. Bacterial biosynthesis of alginates. J Chem Technol
Biotechnol. 2010 Jun 1;85(6):752–9.
[10] Wang L, Shansky J, Borselli C, Mooney D, Vandenburgh H. Design and fabrication of a biodegradable,
covalently crosslinked shape-memory alginate scaffold for cell and growth factor delivery. Tissue Eng
Part A. 2012 May 30;18(19-20):2000–7.
[11] Lee KY, Rowley JA, Eiselt P, Moy EM, Bouhadir KH, Mooney DJ. Controlling mechanical and swelling
properties of alginate hydrogels independently by cross-linker type and cross-linking density.
Macromolecules. 2000 May 1;33(11):4291–4.
[12] Park H, Kang S-W, Kim B-S, Mooney DJ, Lee KY. Shear-reversibly crosslinked alginate hydrogels for tissue
engineering.Macromol Biosci . 2009 Sep 9;9(9):895–901.
[13] Liling G, Di Z, Jiachao X, Xin G, Xiaoting F, Qing Z. Effects of ionic crosslinking on physical and
mechanical properties of alginate mulching films. Carbohydr Polym. 2016 Jan 20;136:259–65.
[14] Samorezov JE, Morlock CM, Alsberg E. Dual ionic and photo-crosslinked alginate hydrogels for
micropatterned spatial control of material properties and cell behavior. Bioconjug Chem. 2015 Jul
15;26(7):1339–47.
[15] Zehnder T, Sarker B, Boccaccini AR, Detsch R. Evaluation of an alginate-gelatine crosslinked hydrogel for
bioplotting. Biofabrication. 2015 Jun;7(2):025001.
[16] Sarker B, Rompf J, Silva R, Lang N, Detsch R, Kaschta J, et al. Alginate-based hydrogels with improved
adhesive properties for cell encapsulation. Int J Biol Macromol. 2015 Jul;78:72–8.
[17] Li C, Zhao S, Zhao Y, Qian Y, Li J, Yin Y. Chemically crosslinked alginate porous microcarriers modified
with bioactive molecule for expansion of human hepatocellular carcinoma cells. J Biomed Mater Res B
Appl Biomater . 2014 Nov;102(8):1648–58.
[18] Rhim J-W. Physical and mechanical properties of water resistant sodium alginate films. LWT - Food Sci
Technol. 2004 May;37(3):323–30.
[19] Jianqi H, Hong H, Lieping S, Genghua G. Comparison of calcium alginate film with collagen membrane
for guided bone regeneration in mandibular defects in rabbits. J Oral Maxillofac Surg Off J Am Assoc Oral
Maxillofac Surg. 2002 Dec;60(12):1449–54.
[20] Liberski AR, Delaney JT, Schäfer H, Perelaer J, Schubert US. Organ weaving: woven threads and
sheets as a step towards a new strategy for artificial organ development.Macromol Biosci . 2011 Nov
10;11(11):1491–8.
[21] Onoe H, Okitsu T, Itou A, Kato-Negishi M, Gojo R, Kiriya D, et al. Metre-long cell-laden microfibres exhibit
tissue morphologies and functions. Nat Mater . 2013 Jun;12(6):584–90.
[22] Yoon H, Ahn S, Kim G. Three-dimensional polycaprolactone hierarchical scaffolds supplemented with
natural biomaterials to enhance mesenchymal stem cell proliferation.Macromol Rapid Commun. 2009
Oct 1;30(19):1632–7.
[23] Swain S, Behera A, Beg S, Patra CN, Dinda SC, Sruti J, et al. Modified alginate beads for mucoad-
hesive drug delivery system: an updated review of patents. Recent Pat Drug Deliv Formul. 2012
Dec;6(3):259–77.
[24] Jeon O, Alt DS, Ahmed SM, Alsberg E. The effect of oxidation on the degradation of photocrosslinkable
alginate hydrogels. Biomaterials. 2012 May;33(13):3503–14.
[25] Lee KY, Mooney DJ. Alginate: properties and biomedical applications. Prog Polym Sci . 2012
Jan;37(1):106–26.
Page 23 of 25
Liberski et al. GCSP 2016:4
[26] Finosh GT, Jayabalan M. Regenerative therapy and tissue engineering for the treatment of end-stage
cardiac failure: new developments and challenges. Biomatter . 2012 Mar;2(1):1–14.
[27] Dar A, Shachar M, Leor J, Cohen S. Optimization of cardiac cell seeding and distribution in 3d porous
alginate scaffolds. Biotechnol Bioeng. 2002 Nov 5;80(3):305–12.
[28] Leor J, Aboulafia-Etzion S, Dar A, Shapiro L, Barbash IM, Battler A, et al. Bioengineered cardiac grafts: A
new approach to repair the infarcted myocardium? Circulation. 2000 Nov 7;102(19 Suppl 3):III56–61.
[29] Duan B, Hockaday LA, Kang KH, Butcher JT. 3d bioprinting of heterogeneous aortic valve conduits with
alginate/gelatin hydrogels. J Biomed Mater Res A. 2013 May 1;101A(5):1255–64.
[30] Zmora S, Glicklis R, Cohen S. Tailoring the pore architecture in 3-d alginate scaffolds by controlling the
freezing regime during fabrication. Biomaterials. 2002 oct;23(20):4087–94.
[31] Shapiro L, Cohen S. Novel alginate sponges for cell culture and transplantation. Biomaterials. 1997
Apr;18(8):583–90.
[32] Ruvinov E, Cohen S. Alginate biomaterial for the treatment of myocardial infarction: Progress,
translational strategies, and clinical outlook: From ocean algae to patient bedside. Adv Drug Deliv Rev .
2016 Jan 15;96:54–76.
[33] Deshpande PC, Tilwankar AK, Asolekar SR. A novel approach to estimating potential maximum heavy
metal exposure to ship recycling yard workers in alang, india. Sci Total Environ. 2012 Nov 1;438:304–11.
[34] Houston MC. The role of mercury and cadmium heavy metals in vascular disease, hypertension,
coronary heart disease, and myocardial infarction. Altern Ther Health Med . 2007 Apr;13(2):S128–33.
[35] Rauter AP. Carbohydrate chemistry: Chemical and biological approaches. Royal Society of Chemistry;
2011. 413 p.
[36] Tani T, Horiguchi Y. Effects of formaldehyde on cardiac function. Jpn J Pharmacol. 1990 Apr;52(4):563–72.
[37] Vita JA. Polyphenols and cardiovascular disease: effects on endothelial and platelet function. Am J Clin
Nutr . 2005 Jan 1;81(1):292S–297S.
[38] Mennen LI, Walker R, Bennetau-Pelissero C, Scalbert A. Risks and safety of polyphenol consumption. Am
J Clin Nutr . 2005 Jan 1;81(1):326S–329S.
[39] Charalambous BM, Stephens RCM, Feavers IM. Montgomery HE. role of bacterial endotoxin in chronic
heart failure: the gut of the matter. Shock Augusta Ga. 2007 Jul;28(1):15–23.
[40] Lanza R, Langer R, Vacanti JP. Principles of tissue engineering. Academic Press; 2013. 1937 p.
[41] Wong TY, Preston LA, Schiller NL. Alginate lyase: Review of major sources and enzyme characteris-
tics, structure-function analysis, biological roles, and applications. Annu Rev Microbiol. 2000 Oct
1;54(1):289–340.
[42] Wargacki AJ, Leonard E, Win MN, Regitsky DD, Santos CNS, Kim PB, et al. An engineered microbial
platform for direct biofuel production from brown macroalgae. Science. 2012 Jan 20;335(6066):308–13.
[43] Senni K, Pereira J, Gueniche F, Delbarre-Ladrat C, Sinquin C, Ratiskol J, et al. Marine polysaccharides:
A source of bioactive molecules for cell therapy and tissue engineering.Mar Drugs. 2011 Sep
23;9(9):1664–81.
[44] Gandhi JK, Opara EC, Brey EM. Alginate-based strategies for therapeutic vascularization. Ther Deliv .
2013 Mar;4(3):327–41.
[45] LeRoux MA, Guilak F, Setton LA. Compressive and shear properties of alginate gel: effects of sodium
ions and alginate concentration. J Biomed Mater Res. 1999 Oct;47(1):46–53.
[46] Wan LQ, Jiang J, Arnold DE, Guo XE, Lu HH, Mow VC. Calcium concentration effects on the mechan-
ical and biochemical properties of chondrocyte-alginate constructs. Cell Mol Bioeng. 2008 Mar
1;1(1):93–102.
[47] Reynolds RM, Padfield PL, Seckl JR. Disorders of sodium balance. BMJ . 2006 Mar 25;332(7543):702–5.
[48] Al-Shamkhani A, Duncan R. Radioiodination of alginate via covalently-bound tyrosinamide allows
monitoring of its fate in vivo. J Bioact Compat Polym. 1995 Jan 1;10(1):4–13.
[49] Bouhadir KH, Lee KY, Alsberg E, Damm KL, Anderson KW, Mooney DJ. Degradation of partially oxidized
alginate and its potential application for tissue engineering. Biotechnol Prog. 2001 Oct;17(5):945–50.
[50] Alsberg E, Kong HJ, Hirano Y, Smith MK, Albeiruti A, Mooney DJ. Regulating bone formation via controlled
scaffold degradation. J Dent Res. 2003 Nov;82(11):903–8.
[51] Fearnley CJ, Roderick HL, Bootman MD. Calcium signaling in cardiac myocytes. Cold Spring Harb
Perspect Biol. 2011 Nov;3(11):a004242.
[52] Marks AR. Calcium and the heart: A question of life and death. J Clin Invest . 2003 Mar 1;111(5):597–600.
[53] Landa N, Miller L, Feinberg MS, Holbova R, Shachar M, Freeman I, et al. Effect of injectable alginate
implant on cardiac remodeling and function after recent and old infarcts in rat. Circulation. 2008 Mar
18;117(11):1388–96.
[54] Sabbah HN, Wang M, Gupta RC, Rastogi S, Ilsar I, Sabbah MS, et al. Augmentation of left ventricular wall
thickness with alginate hydrogel implants improves left ventricular function and prevents progressive
remodeling in dogs with chronic heart failure. JACC Heart Fail. 2013 Jun 1;1(3):252–8.
[55] Lee LC, Zhihong Z, Hinson A, Guccione JM. Reduction in left ventricular wall stress and improvement in
function in failing hearts using algisyl-LVR. J Vis Exp. 2013 Apr 8;50096–102.
[56] Lee RJ, Hinson A, Helgerson S, Bauernschmitt R, Sabbah HN. Polymer-based restoration of left
ventricular mechanics. Cell Transplant . 2013 Mar 1;22(3):529–33.
[57] Lee LC, Wall ST, Klepach D, Ge L, Zhang Z, Lee RJ, et al. Algisyl-LVRTM with coronary artery bypass
grafting reduces left ventricular wall stress and improves function in the failing human heart. Int J
Cardiol. 2013 Oct 3;168(3):2022–8.
Page 24 of 25
Liberski et al. GCSP 2016:4
[58] Lim GB. Heart failure: Alginate-hydrogel in chronic HF. Nat Rev Cardiol. 2015 Aug;12(8):443–443.
[59] Anker SD, Coats AJS, Cristian G, Dragomir D, Pusineri E, Piredda M, et al. A prospective comparison
of alginate-hydrogel with standard medical therapy to determine impact on functional capacity and
clinical outcomes in patients with advanced heart failure (AUGMENT-HF trial). Eur Heart J . 2015 Sep
7;36(34):2297–309.
[60] Costanzo MR, Ivanhoe RJ, Kao A, Anand IS, Bank A, Boehmer J, et al. Prospective evaluation of elastic
restraint to lessen the effects of heart failure (PEERLES S-HF) trial. J Card Fail. 2012 Jun;18(6):446–58.
[61] Mazzaferri EL, Gradinac S, Sagic D, Otasevic P, Hasan AK, Goff TL, et al. Percutaneous left ventricular
partitioning in patients with chronic heart failure and a prior anterior myocardial infarction: Results
of the percutaneous ventricular restoration in chronic heart failure patients trial. Am Heart J . 2012
May;163(5):812–20.e1.
[62] Cheng Y, Aboodi MS, Wechsler AS, Kaluza GL, Granada JF, Van Bladel K, et al. Epicardial catheter-based
ventricular reconstruction: a novel therapy for ischaemic heart failure with anteroapical aneurysm.
Interact Cardiovasc Thorac Surg. 2013 Dec;17(6):915–22.
[63] Blandino A, Macías M, Cantero D. Formation of calcium alginate gel capsules: Influence of sodium
alginate and cacl2 concentration on gelation kinetics. J Biosci Bioeng. 1999 Feb 1;88(6):686–9.
[64] Kanakis J, Malkaj P, Petroheilos J, Dalas E. The crystallization of calcium carbonate on porcine
and human cardiac valves and the antimineralization effect of sodium alginate. J Cryst Growth.
2001;223(4):557–64.
[65] Leor J, Tuvia S, Guetta V, Manczur F, Castel D, Willenz U, et al. Intracoronary injection of in situ forming
alginate hydrogel reverses left ventricular remodeling after myocardial infarction in swine. J Am Coll
Cardiol. 2009 Sep 8;54(11):1014–23.
[66] Ma Y, Feng Q. Alginate hydrogel-mediated crystallization of calcium carbonate. J Solid State Chem. 2011
May;184(5):1008–15.
[67] Lee CSD, Moyer HR, Gittens RAI, Williams JK, Boskey AL, Boyan BD, et al. Regulating in vivo calcification
of alginate microbeads. Biomaterials. 2010 Jun;31(18):4926–34.
[68] Frey N, Linke A, Süselbeck T, Müller-Ehmsen J, Vermeersch P, Schoors D, et al. Intracoronary delivery
of injectable bioabsorbable scaffold (IK-5001) to treat left ventricular remodeling after ST-elevation
myocardial infarction: a first-in-man study. Circ Cardiovasc Interv . 2014 Dec;7(6):806–12.
[69] Al-Shamkhani A, Duncan R. Radioiodination of alginate via covalently-bound tyrosinamide allows
monitoring of its fate in vivo. J Bioact Compat Polym. 1995 Jan 1;10(1):4–13.
[70] Tønnesen HH, Karlsen J. Alginate in drug delivery systems. Drug Dev Ind Pharm. 2002 Jul;28(6):621–30.
[71] Eral HB, López-Mejías V, O’mahony M, Trout BL, Myerson AS, Doyle PS. Biocompatible alginate microgel
particles as heteronucleants and encapsulating vehicles for hydrophilic and hydrophobic drugs. Cryst
Growth Des. 2014 Apr 2;14(4):2073–82.
[72] Chan AW, Whitney RA, Neufeld RJ. Kinetic controlled synthesis of PH-responsive network alginate.
Biomacromolecules. 2008 Sep;9(9):2536–45.
[73] Chu H, Wang Y. Therapeutic angiogenesis: controlled delivery of angiogenic factors. Ther Deliv . 2012
Jun;3(6):693–714.
[74] Silva EA, Mooney DJ. Spatiotemporal control of vascular endothelial growth factor delivery from
injectable hydrogels enhances angiogenesis. J Thromb Haemost . 2007 Mar;5(3):590–8.
[75] Ruvinov E, Leor J, Cohen S. The effects of controlled HGF delivery from an affinity-binding alginate
biomaterial on angiogenesis and blood perfusion in a hindlimb ischemia model. Biomaterials. 2010
Jun;31(16):4573–82.
[76] Hao X, Silva EA, Månsson-Broberg A, Grinnemo K-H, Siddiqui AJ, Dellgren G, et al. Angiogenic effects
of sequential release of VEGF-A165 and PDGF-BB with alginate hydrogels after myocardial infarction.
Cardiovasc Res. 2007 Jul 1;75(1):178–85.
[77] Mihardja SS, Sievers RE, Lee RJ. The effect of polypyrrole on arteriogenesis in an acute rat infarct model.
Biomaterials. 2008 Nov;29(31):4205–10.
[78] Dvir T, Timko BP, Brigham MD, Naik SR, Karajanagi SS, Levy O, et al. Nanowired three dimensional
cardiac patches. Nat Nanotechnol. 2011 Sep 25;6(11):720–5.
[79] Bishop MJ, Plank G. The role of fine-scale anatomical structure in the dynamics of reentry in
computational models of the rabbit ventricles. J Physiol. 2012 Sep 15;590(18):4515–35.
[80] Hagège AA, Marolleau J-P, Vilquin J-T, Alhéritière A, Peyrard S, Duboc D, et al. Skeletal myoblast
transplantation in ischemic heart failure: long-term follow-up of the first phase I cohort of patients.
Circulation. 2006 Jul 4;114(1 Suppl):I108–13.
[81] Sears SF, Shea JB, Conti JB. Cardiology patient page. how to respond to an implantable cardioverter-
defibrillator shock. Circulation. 2005 Jun 14;111(23):e380–2.
[82] Menasché P, Vanneaux V, Hagège A, Bel A, Cholley B, Cacciapuoti I, et al. Human embryonic stem cell-
derived cardiac progenitors for severe heart failure treatment: first clinical case report. Eur Heart J . 2015
Aug 7;36(30):2011–7.
[83] Singelyn JM, Christman KL. Injectable materials for the treatment of myocardial infarction and heart
failure: the promise of decellularized matrices. J Cardiovasc Transl Res. 2010 Oct;3(5):478–86.
[84] Singelyn JM, Sundaramurthy P, Johnson TD, Schup-Magoffin PJ, Hu DP, Faulk DM, et al. Catheter-
deliverable hydrogel derived from decellularized ventricular extracellular matrix increases endogenous
cardiomyocytes and preserves cardiac function post-myocardial infarction. J Am Coll Cardiol. 2012 Feb
21;59(8):751–63.
Page 25 of 25
Liberski et al. GCSP 2016:4
[85] Dvir T, Kedem A, Ruvinov E, Levy O, Freeman I, Landa N, et al. Prevascularization of cardiac patch on the
omentum improves its therapeutic outcome. Proc Natl Acad Sci USA. 2009 Sep 1;106(35):14990–5.
[86] Yu J, Gu Y, Du KT, Mihardja S, Sievers RE, Lee RJ. The effect of injected RGD modified alginate on
angiogenesis and left ventricular function in a chronic rat infarct model. Biomaterials. 2009
Feb;30(5):751–6.
[87] Li Q, Wang Z, Zhang S, Zheng W, Zhao Q, Zhang J, et al. Functionalization of the surface of electrospun
poly(epsilon-caprolactone) mats using zwitterionic poly(carboxybetaine methacrylate) and cell-
specific peptide for endothelial progenitor cells capture.Mater Sci Eng C Mater Biol Appl. 2013 Apr
1;33(3):1646–53.
[88] Yu J, Du KT, Fang Q, Gu Y, Mihardja SS, Sievers RE, et al. The use of human mesenchymal stem cells
encapsulated in RGD modified alginate microspheres in the repair of myocardial infarction in the rat.
Biomaterials. 2010 Sep;31(27):7012–20.
[89] Raynaud CM, Yacoub MH. Clinical trials of bone marrow derived cells for ischemic heart failure.
time to move on? TIME, SWISS-AMI, CELLWAVE, POSEIDON and C-CURE. Glob Cardiol Sci Pract .
2013;2013(3):207–11.
[90] Tsur-Gang O, Ruvinov E, Landa N, Holbova R, Feinberg MS, Leor J, et al. The effects of peptide-based
modification of alginate on left ventricular remodeling and function after myocardial infarction.
Biomaterials. 2009 Jan;30(2):189–95.
[91] Russo MA, Paolillo M, Sanchez-Hernandez Y, Curti D, Ciusani E, Serra M, et al. A small-molecule RGD-
integrin antagonist inhibits cell adhesion, cell migration and induces anoikis in glioblastoma cells. Int J
Oncol. 2013 Jan;42(1):83–92.
[92] Bertazzo S, Gentleman E, Cloyd KL, Chester AH, Yacoub MH, Stevens MM. Nano-analytical electron
microscopy reveals fundamental insights into human cardiovascular tissue calcification. Nat Mater .
2013 Jun;12(6):576–83.
[93] Ma H-L, Chen T-H, Low-Tone Ho L, Hung S-C. Neocartilage from human mesenchymal stem cells in
alginate: implied timing of transplantation. J Biomed Mater Res A. 2005 Sep 1;74(3):439–46.
[94] Thornton AJ, Alsberg E, Hill EE, Mooney DJ. Shape retaining injectable hydrogels for minimally invasive
bulking. J Urol. 2004 Aug;172(2):763–8.
[95] Davey RB, Sparnon AL, Byard RW. Unusual donor site reactions to calcium alginate dressings. Burns.
2000 Jun 1;26(4):393–8.
[96] Chester AH, Taylor PM. Molecular and functional characteristics of heart-valve interstitial cells. Philos
Trans R Soc B Biol Sci . 2007 Aug 29;362(1484):1437–43.
[97] Thubrikar MJ, Aouad J, Nolan SP. Patterns of calcific deposits in operatively excised stenotic or purely
regurgitant aortic valves and their relation to mechanical stress. Am J Cardiol. 1986 Aug 1;58(3):304–8.
[98] Dalas E, Klouras N, Maniatis C. Inhibition of hydroxyapatite formation by titanocenes. Langmuir . 1992
Mar 1;8(3):1003–6.
[99] Kresak M, Moreno EC, Zahradnik RT, Hay DI. Adsorption of amino acids onto hydroxyapatite. J Colloid
Interface Sci . 1977 Apr 1;59(2):283–92.
[100] Zafar F, Hinton RB, Moore RA, Baker RS, Bryant R, Narmoneva DA, et al. Physiological growth,
remodeling potential, and preserved function of a novel bioprosthetic tricuspid valve: Tubular
bioprosthesis made of small intestinal submucosa-derived extracellular matrix. J Am Coll Cardiol. 2015
Aug 25;66(8):877–88.
[101] Kubiak K, Kurzawa M, Jędrzejczak-Krzepkowska M, Ludwicka MJ, Krawczyk M, Migdalski A, et al.
Complete genome sequence of gluconacetobacter xylinus e25 strain–valuable and effective producer of
bacterial nanocellulose. J Biotechnol. 2014 Apr 20;176:18–9.
[102] Muzzarelli RAA. Biomedical exploitation of chitin and chitosan via mechano-chemical disassembly,
electrospinning, dissolution in imidazolium ionic liquids, and supercritical drying.Mar Drugs. 2011 Sep
9;9(9):1510–33.
[103] Wong C, Shital P, Chen R, Owida A, Morsi Y. Biomimetic electrospun gelatin–chitosan polyurethane for
heart valve leaflets. J Mech Med Biol. 2010 Dec 1;10(04):563–76.
[104] El-Sherbiny IM, Yacoub MH. Hydrogel scaffolds for tissue engineering: Progress and challenges. Glob
Cardiol Sci Pract . 2013 Nov 1;2013(3):316–42.
[105] Wu W, Allen RA, Wang Y. Fast degrading elastomer enables rapid remodeling of a cell-free synthetic
graft into a neo-artery. Nat Med . 2012 Jul;18(7):1148–53.
[106] Gao J, Crapo PM, Wang Y. Macroporous elastomeric scaffolds with extensive micropores for soft tissue
engineering. Tissue Eng. 2006 Apr;12(4):917–25.
[107] Sohier J, Carubelli I, Sarathchandra P, Latif N, Chester AH, Yacoub MH. The potential of anisotropic
matrices as substrate for heart valve engineering. Biomaterials. 2014 Feb;35(6):1833–44.
[108] Ballotta V, Driessen-Mol A, Bouten C, Baaijens FPT. Strain-dependent modulation of macrophage
polarization within scaffolds. Biomaterials. 2014 Jun;35(18):4919–28.
[109] Song K, Nam Y-J, Luo X, Qi X, Tan W, Huang GN, et al. Heart repair by reprogramming non-myocytes with
cardiac transcription factors. Nature. 2012 May 31;485(7400):599–604.
[110] Chester AH, El-Hamamsy I, Butcher JT, Latif N, Bertazzo S, Yacoub MH. The living aortic valve: From
molecules to function. Glob Cardiol Sci Pract . 2014 Jan 29;2014(1):52–77.
